Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202510085 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis) New Drug Phase Ⅱ
N202510096 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of OBI-858 in Subjects with Moderate to Severe Glabellar Lines. New Drug Phase Ⅲ
N202510102 A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis New Drug Phase Ⅱ
N202511022 A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK‑3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) New Drug Phase Ⅲ
N202511028 A Phase 2B Randomized, Double‑Blind, 12-Week Placebo‑Controlled Study With A 12-Week Double-Blind Extension Period To Evaluate The Efficacy, Safety And Tolerability Of Ritlecitinib (PF‑06651600) In Adult Participants With Chronic Spontaneous Urticaria New Drug Phase Ⅱ
N202511044 Clinical Research Protocol for a Transcranial Magnetic Stimulation (TMS) Navigation-Assisted System New Medical Device NA
N202511050 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of OBI-858 in Subjects with Moderate to Severe Glabellar Lines. New Drug Phase Ⅲ
N202511060 KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, With Pembrolizumab With or Without Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) New Drug Phase Ⅰ
N202511081 A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization New Drug Phase Ⅱ
N202511082 A preliminary bioequivalence study to compare two vortioxetine hydrobromide F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
1 2 34 35 36 37 38 39 40 51 52 / 52

TOP